Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given a $13.00 Price Target at HC Wainwright
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) received a $13.00 price target from equities researchers at HC Wainwright in a report released on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 118.86% from the company’s current price.
INO has been the topic of a number of other reports. Aegis reissued a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Maxim Group increased their price objective on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $11.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, April 25th. Finally, Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $19.90.
Shares of Inovio Pharmaceuticals (NASDAQ INO) opened at 5.94 on Thursday. Inovio Pharmaceuticals has a 52 week low of $5.83 and a 52 week high of $11.00. The firm has a 50-day moving average of $7.65 and a 200 day moving average of $6.92. The firm’s market capitalization is $443.28 million.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. During the same period in the prior year, the firm posted ($0.11) EPS. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts expect that Inovio Pharmaceuticals will post ($1.11) EPS for the current fiscal year.
In related news, Director David B. Weiner sold 8,000 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.60% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Private Capital Advisors Inc. bought a new position in Inovio Pharmaceuticals during the second quarter worth approximately $274,000. Credit Suisse AG increased its position in Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares during the period. Metropolitan Life Insurance Co. NY increased its position in Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 4,020 shares during the period. Bank of America Corp DE increased its position in Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 16,845 shares during the period. 27.77% of the stock is currently owned by hedge funds and other institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.